Revenue rises to 7.8m pounds in full year at Oxford Biomedica

Gene-based biopharmaceutical company Oxford BioMedica has reported that revenue rose to 7.8m pounds in the full year 2012 from 7.7m pounds one year earlier.

Gene-based biopharmaceutical company Oxford BioMedica has reported that revenue rose to 7.8m pounds in the full year 2012 from 7.7m pounds one year earlier.

In its preliminary results for the year ending December 31st, the company stated that fundraising of £11.6m was completed in July 2012 with net proceeds £10.1m.

Operational highlights included the Sanofi ocular partnership nearing successful conclusion with $53m committed to date.

The company also reported that the ProSavin Phase I/II study successfully met primary endpoints while industry collaborations validated Oxford BioMedica's 5T4 tumour antigen technology.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "During 2012 we reported positive developments across our core clinical programmes, strengthened our LentiVector technology platform and secured MHRA[UK Medicines and Healthcare products Regulatory Agency] approval for our GMP[good manufacturing practice] manufacturing plant.

"Macroeconomic conditions remain challenging, however sentiment towards the biopharmaceutical sector is improving and we are seeing more interest than ever in personalised medicines and niche disease indications, all of which positions Oxford BioMedica well for further developments in the year ahead."

Oxford BioMedica's share price was up 1.69% to 2.40% to 2.40p at 10:41 on Wednesday.

MF

Most Popular

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Commodity supercycle or not, here’s a metal that’ll still be in demand – tin
Industrial metals

Commodity supercycle or not, here’s a metal that’ll still be in demand – tin

Commodity prices may have come off the boil recently. But for tin, the only way is up. Dominic Frisby picks the best ways to invest.
7 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021